LUCD is the official Nasdaq stock exchange ticker symbol for Lucid Diagnostics Inc., a commercial-stage medical technology and cancer prevention subsidiary focused on developing and commercializing advanced diagnostic tests. Its flagship clinical offering centers on the EsoGuard esophageal DNA test and EsoCheck cell collection device, which are engineered to identify precancerous conditions and prevent esophageal cancer in patients suffering from chronic acid reflux and gastroesophageal disease.